Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RLF-100® (aviptadil acetate) restores barrier function at the endothelial/alveolar interface and thereby protects the lung and other organs from failure. It is under development for the potential treatment of acute and chronic lung disease.
Product Name : Zyesami
Product Type : Peptide
Upfront Cash : Inapplicable
April 17, 2023
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (aviptadil)
Details : RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide (“VIP”) consisting of 28 amino acids. The reported data demonstrated high purity levels at six months at all temperatures tested, including at refrigerated and room temperatur...
Product Name : Zyesami
Product Type : Peptide
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, is under development for certain acute and chronic lung diseases, including pulmonary sarcoidosis.
Product Name : Zyesami
Product Type : Peptide
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relief Therapeutics Stock Plunges After FDA Rejects Covid-19 Emergency Approval
Details : Half-century-old aviptadil, studied over the years for a variety of uses including erectile dysfunction and pulmonary fibrosis, was part of Relief's portfolio when the COVID-19 pandemic began, prompting the company to test it against the new coronavirus.
Product Name : Zyesami
Product Type : Peptide
Upfront Cash : Inapplicable
December 30, 2020
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : NRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Relief, NeuroRx have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration (FDA) in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating Respiratory Failure in patients with Critical COVID-19.
Product Name : Zyesami
Product Type : Peptide
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : NRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The multicenter clinical trial will enroll patients with COVID-19 and respiratory failure in the hopes that RLF-100 can decrease mortality in this condition and help to improve the ability of the patient’s lungs to transfer oxygen to the body.
Product Name : Zyesami
Product Type : Peptide
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : NRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100. RLF-100 is a patented formulation of Aviptadil, which binds to alveolar type 2 cells in the lungs inhibiting pro-inflammatory cytokines.
Product Name : Zyesami
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : NRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable